| Literature DB >> 33573376 |
Claire Le Manach1, Jean Dam1, John G Woodland1, Gurminder Kaur1, Lutete P Khonde1, Christel Brunschwig2, Mathew Njoroge2, Kathryn J Wicht3, André Horatscheck1, Tanya Paquet1, Grant A Boyle1, Liezl Gibhard2, Dale Taylor2, Nina Lawrence2, Tomas Yeo3, Sachel Mok3, Richard T Eastman4, Dorjbal Dorjsuren4, Daniel C Talley4, Hui Guo4, Anton Simeonov4, Janette Reader5, Mariëtte van der Watt5, Erica Erlank6,7, Nelius Venter6,7, Jacek W Zawada6,7, Ayesha Aswat6,7, Luisa Nardini6,7, Theresa L Coetzer8, Sonja B Lauterbach8, Belinda C Bezuidenhout8, Anjo Theron9, Dalu Mancama9, Lizette L Koekemoer6,7, Lyn-Marie Birkholtz5, Sergio Wittlin10,11, Michael Delves12,13, Sabine Ottilie14, Elizabeth A Winzeler14, Thomas W von Geldern15, Dennis Smith16, David A Fidock3,17, Leslie J Street1, Gregory S Basarab1, James Duffy18, Kelly Chibale1,19.
Abstract
A novel diazaspiro[3.4]octane series was identified from a Plasmodium falciparum whole-cell high-throughput screening campaign. Hits displayed activity against multiple stages of the parasite lifecycle, which together with a novel sp3-rich scaffold provided an attractive starting point for a hit-to-lead medicinal chemistry optimization and biological profiling program. Structure-activity-relationship studies led to the identification of compounds that showed low nanomolar asexual blood-stage activity (<50 nM) together with strong gametocyte sterilizing properties that translated to transmission-blocking activity in the standard membrane feeding assay. Mechanistic studies through resistance selection with one of the analogues followed by whole-genome sequencing implicated the P. falciparum cyclic amine resistance locus in the mode of resistance.Entities:
Year: 2021 PMID: 33573376 DOI: 10.1021/acs.jmedchem.1c00034
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446